stockrowNatera, Inc.
NTRA Healthcare Diagnostics & Research
Natera, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 35.9% from fiscal 2024.
- Revenue
- +34.1%
- EPS
- +34.4%
- Free cash flow
- −85.8%
- Total debt
- −0.06%
Quarter to September 2026, against a year earlier
Follow NTRA
Alert me
Natera, Inc. (NTRA) Shares outstanding
Natera, Inc.'s shares outstanding at the end of fiscal 2025 was $136.7M, up 9.62% from $124.7M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $144.1M. Over the past ten years it has ranged from $26.2M (fiscal 2015) to $136.7M (fiscal 2025) — the current reading is the highest in ten years. Natera, Inc. ranks 11th of 49 Diagnostics & Research companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $136.7M | 9.62% |
| FY2024 | $124.7M | 8.45% |
| FY2023 | $115.0M | 16.86% |
| FY2022 | $98.4M | 8.67% |
| FY2021 | $90.6M | 11.78% |
| FY2020 | $81.0M | 16.47% |
| FY2019 | $69.6M | 20.24% |
| FY2018 | $57.8M | 7.92% |
| FY2017 | $53.6M | 3.93% |
| FY2016 | $51.6M | 96.82% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $144.1M | 0.55% |
| Jun 2026 | $143.3M | 1.26% |
| Mar 2026 | $141.5M | 3.50% |
| Dec 2025 | $136.7M | (0.34%) |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| A Agilent Technologies, Inc. compare | $283.0M |
| IQV IQVIA Holdings Inc. compare | $167.0M |
| ILMN Illumina, Inc. compare | $154.0M |
| NTRA Natera, Inc. | $144.1M |
| DGX Quest Diagnostics Incorporated compare | $112.0M |
| WAT Waters Corporation compare | $98.7M |
| LH Labcorp Holdings Inc. compare | $81.6M |
| IDXX IDEXX Laboratories, Inc. compare | $79.0M |
| MTD Mettler-Toledo International, Inc. compare | $20.2M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on NTRA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement